Trial intelligence / Profile preview

PETERPEN

2024-518583-13-00Phase 4Authorised

Sponsor: Azienda Ospedaliera Universitaria Policlinico
Start: Sep 2025
Modality: Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, randomised trial in bloodstream infection (BSI), Enterobacteriaceae infection and Cephalosporin-resistant Enterobacteriaceae infection (ESBL-E) comparing Meropenem arm with Piperacillin + Tazobactam arm (2 arms). Primary endpoint: Treatment failure at day 7 from randomization. Planned start Sep 2025; status: authorised.

Drugs

meropenempiperacillintazobactam

Conditions

bloodstream infection (BSI)Enterobacteriaceae infectionCephalosporin-resistant Enterobacteriaceae infection (ESBL-E)

Beyond the preview

Go deeper on 2024-518583-13-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-518583-13-00.